Immune inflammation at the crossroads of chronic obstructive pulmonary disease and asthma: a bibliometric and visualized analysis from 2016 to 2025
Background Chronic obstructive pulmonary disease (COPD) and asthma are chronic airway diseases in which immune-inflammatory dysregulation plays a central role in disease progression, exacerbation, airway remodeling, and therapeutic heterogeneity. However, the global research landscape and emerging research trends at the intersection of immune inflammation, COPD, and asthma remain unclear. Objective This study aimed to map the global trends, knowledge structure, research hotspots, emerging research trends, and China-US differences in immune inflammation research related to COPD and asthma from 2016 to 2025. Methods Publications were retrieved from the Web of Science Core Collection (WOSCC) between January 1, 2016 and December 31, 2025. Of 2660 initially identified records, 1862 publications were included after screening, comprising 1139 original articles and 723 reviews. A PubMed dataset was also constructed for cross-database comparison; 709 of 1189 retrieved records were retained. VOSviewer, CiteSpace, and R-bibliometrix were used to analyze publication trends, country, institution, and author contributions, highly cited articles, co-cited references, keyword co-occurrence, thematic clusters, burst terms, and China-US subgroup patterns. Results Research output increased overall during 2016–2025. Annual WOSCC publications rose from 158 in 2016 to 226 in 2025, while PubMed records increased from 54 to 101. China produced the most publications (467), followed by the United States (374). US-affiliated publications showed higher citation metrics: 17,336 citations, an H-index of 67, and higher average citations. Imperial College London, the University of Newcastle, and Harvard University were among the leading institutions. Keyword and clustering analyses identified asthma, COPD, inflammation, airway inflammation, oxidative stress, eosinophils, biomarkers, and airway remodeling as major research themes. Burst detection indicated increasing research attention to Mendelian randomization, network pharmacology, mepolizumab, the NLRP3 inflammasome, and phase 2a trials. China-focused studies emphasized oxidative stress, inflammatory responses, acute exacerbation, metabolomics, and causal inference, whereas US studies were more closely associated with clinical trials, biologics, eosinophilic inflammation, and immune-targeted therapy. The PubMed comparison showed broadly consistent trends and thematic patterns. Conclusion Immune inflammation has become a key framework for understanding disease heterogeneity and precision treatment in COPD and asthma. Future studies should strengthen comparative mechanistic research, biomarker discovery, multi-omics integration, targeted therapy, and clinical translation.
Authors
- Wenjing Dai
- Chunfei Li
- Yongyan Zhao
- Xiaolu Chen
Institutions
- Chengdu Medical College (CN)
- First Affiliated Hospital of Chengdu Medical College (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3389/fmed.2026.1997974
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00